Sun Pharma Advanced Research Company Limited (SPARC.NS)
INR 145.25
(-0.48%)
INR 145.25
(-0.48%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.87 Billion INR | -73.96% |
| 2022 | -2.22 Billion INR | -9.43% |
| 2021 | -2.03 Billion INR | -34.58% |
| 2020 | -1.51 Billion INR | 51.62% |
| 2019 | -3.12 Billion INR | -114.81% |
| 2018 | -1.45 Billion INR | 26.18% |
| 2017 | -1.96 Billion INR | -63.8% |
| 2016 | -1.2 Billion INR | -71.83% |
| 2015 | -699.92 Million INR | -77.11% |
| 2014 | -395.2 Million INR | -230.32% |
| 2013 | 303.24 Million INR | 234.81% |
| 2012 | -224.94 Million INR | 68.86% |
| 2011 | -722.32 Million INR | -749.72% |
| 2010 | -85 Million INR | 60.56% |
| 2009 | -215.53 Million INR | -135.8% |
| 2008 | -91.4 Million INR | -87.2% |
| 2007 | -48.82 Million INR | 2.03% |
| 2006 | -49.84 Million INR | 0.0% |
| 2005 | - INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -959 Million INR | 9.35% |
| 2024 Q2 | -1.07 Billion INR | -11.92% |
| 2023 Q4 | -1.05 Billion INR | -6.16% |
| 2023 Q3 | -996.5 Million INR | -15.31% |
| 2023 Q2 | -864.2 Million INR | 9.37% |
| 2023 Q1 | -953.5 Million INR | -16.29% |
| 2023 FY | -3.87 Billion INR | -73.96% |
| 2022 Q3 | 101.5 Million INR | 114.84% |
| 2022 Q1 | -823.5 Million INR | -15.91% |
| 2022 FY | -2.22 Billion INR | -9.43% |
| 2022 Q4 | -819.9 Million INR | -907.78% |
| 2022 Q2 | -684 Million INR | 16.94% |
| 2021 Q2 | -551.4 Million INR | 10.15% |
| 2021 Q4 | -710.45 Million INR | -348.52% |
| 2021 Q1 | -613.7 Million INR | -8.2% |
| 2021 Q3 | -158.4 Million INR | 71.27% |
| 2021 FY | -2.03 Billion INR | -34.58% |
| 2020 Q2 | -834.9 Million INR | -247.27% |
| 2020 Q3 | -676.2 Million INR | 19.01% |
| 2020 FY | -1.51 Billion INR | 51.62% |
| 2020 Q4 | -567.18 Million INR | 16.12% |
| 2020 Q1 | 566.9 Million INR | 156.95% |
| 2019 Q4 | -995.43 Million INR | -79.33% |
| 2019 Q3 | -555.1 Million INR | 12.11% |
| 2019 FY | -3.12 Billion INR | -114.81% |
| 2019 Q1 | -941.9 Million INR | -907.29% |
| 2019 Q2 | -631.6 Million INR | 32.94% |
| 2018 FY | -1.45 Billion INR | 26.18% |
| 2018 Q1 | -644.8 Million INR | -2700.0% |
| 2018 Q3 | -690.2 Million INR | -2575.19% |
| 2018 Q4 | -93.5 Million INR | 86.45% |
| 2018 Q2 | -25.8 Million INR | 96.0% |
| 2017 Q4 | 24.8 Million INR | 104.27% |
| 2017 FY | -1.96 Billion INR | -63.8% |
| 2017 Q3 | -580.7 Million INR | 7.19% |
| 2017 Q2 | -625.7 Million INR | 20.64% |
| 2017 Q1 | -788.4 Million INR | -144.31% |
| 2016 Q1 | -364.1 Million INR | -280.06% |
| 2016 FY | -1.2 Billion INR | -71.83% |
| 2016 Q4 | -322.7 Million INR | 51.35% |
| 2016 Q3 | -663.3 Million INR | -550.0% |
| 2016 Q2 | 147.4 Million INR | 140.48% |
| 2015 Q3 | -410.2 Million INR | -131.23% |
| 2015 Q4 | -95.8 Million INR | 76.65% |
| 2015 FY | -699.92 Million INR | -77.11% |
| 2015 Q1 | -16.5 Million INR | 82.45% |
| 2015 Q2 | -177.4 Million INR | -975.15% |
| 2014 Q3 | -189.1 Million INR | -1186.39% |
| 2014 Q1 | -97.4 Million INR | -288.7% |
| 2014 Q4 | -94 Million INR | 50.29% |
| 2014 FY | -395.2 Million INR | -230.32% |
| 2014 Q2 | -14.7 Million INR | 84.91% |
| 2013 Q3 | 309.7 Million INR | 504.84% |
| 2013 Q1 | 95.1 Million INR | -78.4% |
| 2013 FY | 303.24 Million INR | 234.81% |
| 2013 Q4 | -25.05 Million INR | -108.09% |
| 2013 Q2 | -76.5 Million INR | -180.44% |
| 2012 Q2 | -241.2 Million INR | -31.66% |
| 2012 Q1 | -183.2 Million INR | 15.15% |
| 2012 FY | -224.94 Million INR | 68.86% |
| 2012 Q4 | 440.35 Million INR | 282.79% |
| 2012 Q3 | -240.9 Million INR | 0.12% |
| 2011 FY | -722.32 Million INR | -749.72% |
| 2011 Q4 | -215.92 Million INR | -20.63% |
| 2011 Q3 | -179 Million INR | 0.0% |
| 2010 FY | -85 Million INR | 60.56% |
| 2009 FY | -215.53 Million INR | -135.8% |
| 2008 FY | -91.4 Million INR | -87.2% |
| 2007 FY | -48.82 Million INR | 2.03% |
| 2006 FY | -49.84 Million INR | 0.0% |
| 2005 FY | - INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 449.72 Million INR | 961.0% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | 54698.689% |
| Caplin Point Laboratories Limited | 4.57 Billion INR | 184.713% |
| FDC Limited | 3.05 Billion INR | 226.862% |
| Gufic Biosciences Limited | 861.35 Million INR | 549.54% |
| Hikal Limited | 696 Million INR | 656.342% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 191.983% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 388.041% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 2751.896% |
| Medico Remedies Limited | 82.9 Million INR | 4770.348% |
| Nectar Lifesciences Limited | 49.95 Million INR | 7852.03% |
| Par Drugs and Chemicals Limited | 145.01 Million INR | 2770.257% |
| RPG Life Sciences Limited | 876.6 Million INR | 541.722% |
| Sequent Scientific Limited | -358.69 Million INR | -979.522% |
| Shilpa Medicare Limited | 318.74 Million INR | 1314.819% |
| Sigachi Industries Limited | 571.8 Million INR | 777.182% |
| Themis Medicare Limited | 435.23 Million INR | 989.66% |
| Unichem Laboratories Limited | -704.74 Million INR | -449.44% |
| Venus Remedies Limited | 284.9 Million INR | 1459.084% |
| Wanbury Limited | 559.56 Million INR | 791.993% |
| ZIM Laboratories Limited | 172.46 Million INR | 2345.187% |
| Lupin Limited | 19.14 Billion INR | 120.226% |
| Innova Captab Limited | 943.45 Million INR | 510.423% |
| Ind-Swift Limited | 142.31 Million INR | 2820.861% |
| Bajaj HealthCare Limited | -837.93 Million INR | -362.107% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 112.204% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 31.755% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 339.746% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | -4168.372% |
| Morepen Laboratories Limited | 961.59 Million INR | 502.677% |
| Laurus Labs Limited | 1.6 Billion INR | 341.18% |
| Aarti Drugs Limited | 1.71 Billion INR | 325.888% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 182.231% |
| Alembic Limited | 2.68 Billion INR | 244.15% |
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 162.878% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 74.214% |
| Vaishali Pharma Limited | 7.18 Million INR | 53961.997% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 278.52% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 1823.785% |
| Jubilant Pharmova Limited | 771 Million INR | 602.223% |
| Eris Lifesciences Limited | 3.91 Billion INR | 198.783% |
| Windlas Biotech Limited | 581.87 Million INR | 765.465% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 104.043% |
| Lincoln Pharmaceuticals Limited | 933.04 Million INR | 514.998% |
| Orchid Pharma Limited | 921.66 Million INR | 520.124% |
| Albert David Limited | 754.2 Million INR | 613.409% |
| Hester Biosciences Limited | 188.89 Million INR | 2149.944% |
| Sakar Healthcare Limited | 116.7 Million INR | 3417.772% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 228.951% |
| Procter & Gamble Health Limited | 2 Billion INR | 292.663% |
| Divi's Laboratories Limited | 16 Billion INR | 124.201% |
| Mankind Pharma Limited | 19.12 Billion INR | 120.242% |
| Neuland Laboratories Limited | 3 Billion INR | 229.037% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 170.068% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 110.033% |
| Wockhardt Limited | -4.63 Billion INR | 16.368% |
| Bal Pharma Limited | 73.92 Million INR | 5338.142% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 106.954% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 613.178% |
| Alkem Laboratories Limited | 17.95 Billion INR | 121.563% |
| Valiant Laboratories Limited | 3.19 Million INR | 121255.788% |
| Ajanta Pharma Limited | 8.16 Billion INR | 147.443% |
| Bafna Pharmaceuticals Limited | 73.47 Million INR | 5369.722% |
| Aarey Drugs & Pharmaceuticals Limited | 46.83 Million INR | 8367.323% |
| Granules India Limited | 4.05 Billion INR | 195.535% |
| Medicamen Biotech Limited | 109.31 Million INR | 3642.347% |
| Ipca Laboratories Limited | 5.47 Billion INR | 170.743% |
| Brooks Laboratories Limited | -195.91 Million INR | -1876.398% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 1629.631% |
| Piramal Enterprises Limited | -16.83 Billion INR | 77.0% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 123.377% |
| NATCO Pharma Limited | 13.88 Billion INR | 127.891% |
| Suven Life Sciences Limited | -1.05 Billion INR | -268.507% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | -1862.723% |
| Strides Pharma Science Limited | -706.14 Million INR | -448.353% |
| Indoco Remedies Limited | 984.6 Million INR | 493.27% |
| Alpa Laboratories Limited | 167.76 Million INR | 2408.073% |
| Lasa Supergenerics Limited | -217.3 Million INR | -1681.883% |